Provided by Tiger Trade Technology Pte. Ltd.

NanoViricides

0.9605
+0.01361.44%
Post-market: 0.96050.00000.00%16:10 EDT
Volume:171.55K
Turnover:162.78K
Market Cap:20.72M
PE:-2.00
High:0.9825
Open:0.9400
Low:0.9201
Close:0.9469
52wk High:2.23
52wk Low:0.8500
Shares:21.57M
Float Shares:20.97M
Volume Ratio:0.81
T/O Rate:0.82%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4813
EPS(LYR):-0.6263
ROE:-77.53%
ROA:-44.02%
PB:1.87
PE(LYR):-1.53

Loading ...

NanoViricides Wins DRC Approval to Begin Phase II Trial of NV-387 for MPox

Reuters
·
Nov 10, 2025

NanoViricides Inc. to Present at Spartan Capital Investor Conference in New York City

Reuters
·
Nov 03, 2025

NanoViricides Announces NV-387 Shows Potent Anti-Measles Activity in Phase I Trial

Reuters
·
Oct 29, 2025

NanoViricides Reports Strong Antiviral Activity for NV-387 Against Measles in Preclinical Studies

Reuters
·
Oct 22, 2025

BRIEF-Nanoviricides Says NV-387 Shows Activity Against Measles Virus In Humanized Animal Model

Reuters
·
Oct 21, 2025

NanoViricides: Nv-387 Has Already Completed Phase I Clinical Trial in Healthy Subjects With No Reported Adverse Events

THOMSON REUTERS
·
Oct 20, 2025

NanoViricides: Clinical Lead Drug Nv-387 Has Shown Strong Activity Against Measles Virus in a Humanized Animal Model

THOMSON REUTERS
·
Oct 20, 2025

NanoViricides: Nv-387 Can NOW Be Made Available for Emergency Use Application in Measles Patients to Respond to Spreading Measles Outbreaks

THOMSON REUTERS
·
Oct 20, 2025

NanoViricides Announces Strong Measles Drug Results and Emergency Use Availability

Reuters
·
Oct 20, 2025

NanoViricides Inc. Announces Date for Upcoming Annual Meeting of Stockholders

Reuters
·
Oct 08, 2025

NanoViricides Inc. Announces New Compensation Agreements, Extends President Dr. Anil Diwan’s Contract with $400,000 Salary and Equity Incentives

Reuters
·
Oct 02, 2025

Nanoviricides Q4 EPS $(0.13) Up From $(0.19) YoY

Benzinga
·
Sep 30, 2025

NanoViricides Reports No Revenue for Fiscal Year Ended June 30, 2025; Net Loss Continues as R&D Expenses Rise by $112,000

Reuters
·
Sep 30, 2025